The University of Massachusetts (UMass) Center for Clinical and Translational Science (UMCCTS) was organized with the vision of transforming clinical and translational research (CTR) and education across the five UMass campuses and our clinical partner, UMass Memorial Health Care (UMMHC). Specific goals were to leverage our scientific strengths and unique resources: 1) to accelerate the translation of discoveries into practical, cost effective solutions that improve human health; and 2) to train the next generation of leaders in CTR. Over the past five years, the UMCCTS has fostered a culture of trans-disciplinary collaboration; provided cores, services, and pilot programs; and developed innovative educational and training programs. We have capitalized on our outstanding basic science research to create an ecosystem that accelerates early phase translation and have facilitated the development of nationally recognized programs in community engagement, health disparities, outcomes, and Global Health. Public-private partnerships have positioned UMass campuses as hubs in the Massachusetts (MA) innovation economy. We will continue to build the UMCCTS for statewide, national, and international collaboration and impact by: 1. Building and supporting an innovative and collaborative translational workforce with the knowledge and expertise to advance high impact CTR. Using an active approach to solving real-world problems that combines didactic education, experiential training, and integrated mentorship to facilitate team science, we will expand CTR educational and training opportunities through revamped curricula, a new PhD and postdoctoral training program (linked TL1 award), an enhanced KL2 Scholars program, increased training opportunities and career support for our entire CTR workforce; 2. Engaging stakeholders to build enabling systems and trans- disciplinary teams that provide the scientific expertise, funding, processes, and tools conducive to effective CTR. We will continue to expand public-private partnerships that build out the UMCCTS as a contributing partner in the national CTSA network; we will particularly work to build capacity to identify and advance products for clinical development. We will also collaborate with the CTSA network on testing new approaches to improving the design, completion, and reporting of clinical trials that result in improved population, community, and global health; 3. Integrating translational science across its multiple phases, diverse disciplines, within disadvantaged populations, and across the lifespan. We will capitalize on specific expertise in disparities, LGBT, pediatric, and geriatric research along with successes in community engagement to maximize the impact of our work on health improvement at the local, national, and global levels. 4. Testing new approaches to develop and evaluate the impact of policies, processes, and platforms that support innovation, quality, safety, and efficiency in CTR. Project Summary/Abstract Page 158 Contact PD/PI: Luzuriaga, Katherine

Public Health Relevance

The University of Massachusetts Center for Clinical and Translational Science (UMCCTS) will provide innovative education and career development programs, catalytic pilot grant programs, and cost-effective services and facilities that accelerate the translation of discoveries into practical solutions that improve human health. Project Narrative Page 159

National Institute of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)
Linked Specialized Center Cooperative Agreement (UL1)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1-SRC (99))
Program Officer
Purucker, Mary E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Massachusetts Medical School Worcester
Schools of Medicine
United States
Zip Code
Kapoor, A; Ellis, A; Shaffer, N et al. (2017) Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis. J Thromb Haemost 15:284-294
Strassner, James P; Rashighi, Mehdi; Ahmed Refat, Maggi et al. (2017) Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J Am Acad Dermatol 76:847-855.e5
El-Khatib, Firas H; Balliro, Courtney; Hillard, Mallory A et al. (2017) Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet 389:369-380
Anderson, Melissa L; Wolf Craig, Kelly S; Ziedonis, Douglas M (2017) Deaf people's help-seeking following trauma: Experiences with and recommendations for the Massachusetts behavioral health care system. Psychol Trauma 9:239-248
Aroke, Edwin N; Crawford, Sybil L; Dungan, Jennifer R (2017) Pharmacogenetics of Ketamine-Induced Emergence Phenomena: A Pilot Study. Nurs Res 66:105-114
Kost, Rhonda G; Poppel, Stephen M; Coller, Barry S (2017) Informed consent for next-generation nucleotide sequencing studies: Aiding communication between participants and investigators. J Clin Transl Sci 1:115-120
Afik, Shaked; Bartok, Osnat; Artyomov, Maxim N et al. (2017) Defining the 5? and 3? landscape of the Drosophila transcriptome with Exo-seq and RNaseH-seq. Nucleic Acids Res 45:e95
Kapoor, Alok; Burns, Laura; Foust, Janice B et al. (2017) Show Back: Developing and Testing of a Simulation-Based Assessment Method for Identifying Problems in Self-Management of Medications in Older Adults. J Patient Saf :
Reider Apel, Amanda; d'Espaux, Leo; Wehrs, Maren et al. (2017) A Cas9-based toolkit to program gene expression in Saccharomyces cerevisiae. Nucleic Acids Res 45:496-508
Watkin, Levi B; Mishra, Rabinarayan; Gil, Anna et al. (2017) Unique influenza A cross-reactive memory CD8 T-cell receptor repertoire has a potential to protect against EBV seroconversion. J Allergy Clin Immunol 140:1206-1210

Showing the most recent 10 out of 96 publications